Aurobindo Pharma has reported a modest increase in its Q4 profit, attributed to strong performance in European and growth markets despite a decline in US revenues.
The company achieved a net profit of Rs. 921 crore for the March quarter, reflecting a 2% rise. Revenue also saw a notable increase, climbing 5.6% to Rs. 8,853 crore. However, the US market presented challenges, with revenues dropping 13% year-over-year to Rs. 3,543 crore.
In contrast, Aurobindo's revenues from Europe experienced significant growth, soaring by 30.2%, which helped to mitigate the losses from the US market. Despite these mixed results, the company's EBITDA margins did decline, falling to 20.3% from 21.4% in the previous year.
This performance highlights the shifting dynamics in the pharmaceutical market, where geographic diversification can play a crucial role in balancing revenue streams. Aurobindo's ability to capitalize on growth in Europe suggests a strategic focus that may serve as a model for other firms facing similar challenges in the US market.